Choosing the right initial antiretroviral regimens
- PMID: 11366117
Choosing the right initial antiretroviral regimens
Abstract
AIDS: Thirteen antiretrovirals are currently approved in the U.S., and possibly a dozen more will apply for approval within the next few years. At the same time, only about half of U.S. residents who are HIV-positive are on any kind of treatment. Choosing an effective initial therapy continues to be a major concern. Arguments strongly in favor of using a protease inhibitor (PI) in the initial regimen are included, as are arguments that PIs should be avoided in initial regimens. Pros and cons of beginning therapy with nonnucleoside reverse transcriptase inhibitors (NNRTIs) are also described. Results from the Atlantic Study, which compares protease-containing and protease-sparing regimens, are briefly presented.
Similar articles
-
Nonnucleoside reverse transcriptase inhibitors.AIDS Clin Care. 1997 Oct;9(10):75-7, 79. AIDS Clin Care. 1997. PMID: 11364757
-
Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.HIV Med. 2005 Nov;6(6):396-402. doi: 10.1111/j.1468-1293.2005.00325.x. HIV Med. 2005. PMID: 16268821
-
HIV-1 protease inhibitors.Clin Infect Dis. 2000 Jun;30 Suppl 2:S160-70. doi: 10.1086/313853. Clin Infect Dis. 2000. PMID: 10860901 Review.
-
Standard treatments for HIV, Spring 1997.AIDS Treat News. 1997 Apr 18;(No 269):4-5. AIDS Treat News. 1997. PMID: 11364255
-
Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?AIDS Rev. 2008 Oct-Dec;10(4):205-11. AIDS Rev. 2008. PMID: 19092976 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous